O. Ross McIntyre

5.6k total citations · 1 hit paper
84 papers, 3.6k citations indexed

About

O. Ross McIntyre is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, O. Ross McIntyre has authored 84 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Hematology, 24 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in O. Ross McIntyre's work include Multiple Myeloma Research and Treatments (25 papers), Acute Myeloid Leukemia Research (13 papers) and Cancer Treatment and Pharmacology (13 papers). O. Ross McIntyre is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Acute Myeloid Leukemia Research (13 papers) and Cancer Treatment and Pharmacology (13 papers). O. Ross McIntyre collaborates with scholars based in United States, United Kingdom and Israel. O. Ross McIntyre's co-authors include Charles A. Schiffer, Roger B. Davis, Joseph O. Moore, Bayard L. Powell, Robert J. Mayer, E Frei, George Omura, Philip Schulman, Deborah Berg and Gibbons G. Cornwell and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

O. Ross McIntyre

81 papers receiving 3.3k citations

Hit Papers

Intensive Postremission C... 1994 2026 2004 2015 1994 250 500 750 1000

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Ross McIntyre United States 30 2.0k 1.1k 865 752 579 84 3.6k
K. B. McCredie United States 33 2.0k 1.0× 1.1k 1.0× 900 1.0× 833 1.1× 829 1.4× 86 3.7k
Geoffrey P. Herzig United States 29 1.7k 0.8× 664 0.6× 1.3k 1.6× 563 0.7× 633 1.1× 68 3.8k
H. E. M. Kay United Kingdom 32 1.6k 0.8× 459 0.4× 750 0.9× 875 1.2× 739 1.3× 87 4.1k
Michael Potter United Kingdom 32 1.8k 0.9× 710 0.6× 767 0.9× 760 1.0× 386 0.7× 116 3.3k
Roy S. Weiner United States 27 1.1k 0.6× 507 0.4× 798 0.9× 419 0.6× 236 0.4× 91 2.9k
M. Boogaerts Belgium 38 2.2k 1.1× 572 0.5× 1.2k 1.3× 348 0.5× 1.0k 1.7× 102 4.8k
E. Donnall Thomas United States 35 3.1k 1.6× 551 0.5× 1.1k 1.3× 423 0.6× 836 1.4× 93 5.3k
Bracha Ramot Israel 34 1.1k 0.6× 839 0.7× 671 0.8× 353 0.5× 1.1k 1.9× 220 4.6k
U. Jehn Germany 24 1.1k 0.5× 568 0.5× 827 1.0× 451 0.6× 319 0.6× 125 2.7k
Alexander Fefer United States 32 2.8k 1.4× 382 0.3× 1.4k 1.6× 549 0.7× 664 1.1× 81 4.7k

Countries citing papers authored by O. Ross McIntyre

Since Specialization
Citations

This map shows the geographic impact of O. Ross McIntyre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Ross McIntyre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Ross McIntyre more than expected).

Fields of papers citing papers by O. Ross McIntyre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Ross McIntyre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Ross McIntyre. The network helps show where O. Ross McIntyre may publish in the future.

Co-authorship network of co-authors of O. Ross McIntyre

This figure shows the co-authorship network connecting the top 25 collaborators of O. Ross McIntyre. A scholar is included among the top collaborators of O. Ross McIntyre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Ross McIntyre. O. Ross McIntyre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McIntyre, O. Ross, et al.. (1996). Pilot Survey of Opinions on Data Falsification in Clinical Trials. Cancer Investigation. 14(4). 392–395. 1 indexed citations
2.
Mayer, Robert J., Roger B. Davis, Charles A. Schiffer, et al.. (1994). Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia. New England Journal of Medicine. 331(14). 896–903. 1027 indexed citations breakdown →
3.
Taylor, Jack A., Dale P. Sandler, Clara D. Bloomfield, et al.. (1992). ras Oncogene Activation and Occupational Exposures in Acute Myeloid Leukemia. JNCI Journal of the National Cancer Institute. 84(21). 1626–1632. 61 indexed citations
4.
Dillman, Robert O., Rosemarie Mick, & O. Ross McIntyre. (1989). Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.. Journal of Clinical Oncology. 7(4). 433–438. 129 indexed citations
5.
Cornwell, Gibbons G., T F Pajak, S Kochwa, et al.. (1988). Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.. Journal of Clinical Oncology. 6(9). 1481–1490. 5 indexed citations
6.
Brubaker, Leonard H., Louis R. Wasserman, Judith D. Goldberg, et al.. (1984). Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. American Journal of Hematology. 16(4). 367–373. 12 indexed citations
8.
McIntyre, O. Ross, et al.. (1979). Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGB. Blood. 54(1). 13–22. 72 indexed citations
9.
Kyle, Robert A., Salman Gailani, Barbara R. Seligman, et al.. (1979). Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.. PubMed. 63(8). 1265–9. 17 indexed citations
11.
Maurer, L. Herbert, et al.. (1977). Clinical trial of combined therapy with adriamycin and cis-dichlorodiammineplatinum(II).. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(3). 477–9. 3 indexed citations
12.
Burke, Georgina, et al.. (1977). Anti-keyhole limpet hemocyanin antibody in normal unsensitized individuals. Journal of Allergy and Clinical Immunology. 59(4). 309–313. 22 indexed citations
13.
Wurster‐Hill, Doris H., Gibbons G. Cornwell, & O. Ross McIntyre. (1974). Chromosomal aberrations and neoplasm—a family study. Cancer. 33(1). 72–81. 20 indexed citations
14.
Zacharski, Leo R., Leon W. Hoyer, & O. Ross McIntyre. (1973). Immunologic Identification of Tissue Factor (Thromboplastin) Synthesized by Cultured Fibroblasts. Blood. 41(5). 671–678. 16 indexed citations
15.
O’Keefe, Grant E., et al.. (1972). Human Leukocyte Interferon: The Variation in Normals and Correlation with PHA Transformation. Experimental Biology and Medicine. 140(4). 1263–1269. 16 indexed citations
16.
Salmon, Sydney E., O. Ross McIntyre, & Makio Ogawa. (1971). IgE Myeloma: Total Body Tumor Cell Number and Synthesis of IgE and DNA. Blood. 37(6). 696–705. 19 indexed citations
17.
Zacharski, Leo R. & O. Ross McIntyre. (1971). Procoagulant Synthesis by Cultured Fibroblasts triggered by Cell Adhesion. Nature. 232(5309). 338–339. 18 indexed citations
18.
Eurenius, Karl & O. Ross McIntyre. (1970). The Mechanism of Glucocorticoid Action on the Phytohemagglutinin-Stimulated Lymphocyte. International Archives of Allergy and Immunology. 38(2). 158–167. 3 indexed citations
19.
Eurenius, Karl & O. Ross McIntyre. (1970). Cell Dynamics in Phytohemagglutinin (PHA) Stimulated Guinea-Pig Lymph Node Lymphocyte Cultures. International Archives of Allergy and Immunology. 37(4). 393–408. 2 indexed citations
20.
Paglia, Donald E., William N. Valentine, Marjorie A. Baughan, et al.. (1968). An inherited molecular lesion of erythrocyte pyruvate kinase. Journal of Clinical Investigation. 47(8). 1929–1946. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026